M
Meggan Mackay
Researcher at The Feinstein Institute for Medical Research
Publications - 81
Citations - 4545
Meggan Mackay is an academic researcher from The Feinstein Institute for Medical Research. The author has contributed to research in topics: Systemic lupus erythematosus & Lupus erythematosus. The author has an hindex of 25, co-authored 66 publications receiving 3539 citations. Previous affiliations of Meggan Mackay include Yeshiva University.
Papers
More filters
Journal ArticleDOI
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Michelle Petri,Mimi Y. Kim,Kenneth C. Kalunian,Jennifer M. Grossman,Bevra H. Hahn,Lisa R. Sammaritano,Michael D. Lockshin,Joan T. Merrill,H. Michael Belmont,Anca Askanase,W. Joseph McCune,Michelene Hearth-Holmes,Mary Anne Dooley,Joan M. Von Feldt,Alan Friedman,Mark Tan,John A. Davis,Cronin Me,Betty Diamond,Meggan Mackay,Lisa Sigler,Michael Fillius,Ann Rupel,Frederick Licciardi,Jill P. Buyon +24 more
TL;DR: It is indicated that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable.
Journal ArticleDOI
Combined oral contraceptives in women with systemic lupus erythematosus
Michelle Petri,Mimi Y. Kim,Kenneth C. Kalunian,Jennifer M. Grossman,Bevra H. Hahn,Lisa R. Sammaritano,Michael D. Lockshin,Joan T. Merrill,H. Michael Belmont,Anca Askanase,W. Joseph McCune,Michelene Hearth-Holmes,Mary Anne Dooley,Joan M. Von Feldt,Alan Friedman,Mark Tan,John A. Davis,Cronin Me,Betty Diamond,Meggan Mackay,Lisa Sigler,Michael Fillius,Ann Rupel,Frederick Licciardi,Jill P. Buyon +24 more
TL;DR: This study indicates that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable and is within the prespecified 9 percent margin for noninferiority.
Journal ArticleDOI
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ian N. Bruce,Aidan G. O'Keeffe,Vernon T. Farewell,John G. Hanly,Susan Manzi,Li Su,Dafna D. Gladman,Sang Cheol Bae,Jorge Sanchez-Guerrero,Juanita Romero-Diaz,Caroline Gordon,Daniel J. Wallace,Ann E. Clarke,Sasha Bernatsky,Ellen M. Ginzler,David A. Isenberg,Anisur Rahman,J. T. Merrill,Graciela S. Alarcón,Barri J. Fessler,Paul R. Fortin,Michelle Petri,Kristjan Steinsson,Mary Anne Dooley,Munther A. Khamashta,Rosalind Ramsey-Goldman,Asad Zoma,Gunnar Sturfelt,Ola Nived,Cynthia Aranow,Meggan Mackay,Manuel Ramos-Casals,Ronald F van Vollenhoven,Kenneth C. Kalunian,Guillermo Ruiz-Irastorza,S. Sam Lim,Diane L. Kamen,Christine A. Peschken,Murat Inanc,Murray B. Urowitz +39 more
TL;DR: It is found that several potentially modifiable risk factors for damage accrual are identified and an integrated strategy to address these may improve long-term outcomes.
Journal ArticleDOI
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95.
A.M. Jacobi,Karin Reiter,Meggan Mackay,Cynthia Aranow,Falk Hiepe,Andreas Radbruch,Arne Hansen,Gerd-R. Burmester,Betty Diamond,Peter E. Lipsky,Thomas Dörner +10 more
TL;DR: CD95 is a useful marker to identify CD27- memory B cells with an activated phenotype, which might serve as a biomarker for lupus activity and as a target of further investigations aiming to elucidate the pathogenic potential of these cells and the mechanisms involved in the generation as well as regulation of this CD27-,IgD-,CD95+ memory B cell subset.
Journal ArticleDOI
Treatment of Lupus Nephritis with Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study
Anca Askanase,Margie Byron,Lynette Keyes-Elstein,Patricia Cagnoli,W. Joseph McCune,W. Winn Chatham,Gabriel Contreras,David I. Daikh,Maria Dall'Era,David Wofsy,Anne Davidson,Betty Diamond,Meggan Mackay,Linna Ding,Wendy Gao,Mary Anne Dooley,Hilda Fragoso-Loyo,Jorge Sánchez-Guerrero,David R. Karp,Nancy J. Olsen,Meenakshi Jolly,Kenneth C. Kalunian,Diane L. Kamen,Iris Lee,Marc C. Levesque,S. Sam Lim,Cesar Ramos-Remus,Brad H. Rovin,Peter H. Sayre,Dawn E. Smilek,Patti Tosta,Tammy O. Utset,Swamy Venuturupalli,Robert Winchester +33 more
TL;DR: The potential of abatacept to induce “clinical tolerance,” defined as sustained clinical quiescence of lupus nephritis after discontinuation of immunosuppressive therapy, is assessed.